Alicia K. Morgans, MD, MPH, highlights quality of life data from the phase 3 ARANOTE trial. The phase 3 ARANOTE trial (NCT04736199) showed that the addition of darolutamide (Nubeqa) to androgen ...

David Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones.

Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

A panelist discusses how patient comorbidities like diabetes and liver disease influence abiraterone formulation selection, noting that some physicians worry about steroid effects on blood glucose and ...

Treatment with the Revi System led to durable QOL benefits at 24 months, even among those patients who did not achieve the primary end point. Treatment of urgency urinary incontinence (UUI) with the ...

The FDA has approved a label expansion for Illuccix (kit for the preparation of gallium Ga-68 gozetotide, for injection) to include use in patient selection for prostate-specific membrane antigen ...

Panelists discuss how the new PET technology could identify lymph node involvement not visible on conventional imaging, providing actionable information for surgical planning or indicating the need ...

A panelist discusses how food significantly affects abiraterone absorption, particularly fatty meals, which can increase absorption to dangerous levels, making the microformulation advantageous by ...

Arm D of the trial is assessing the performance of [68Ga]Ga-DPI-4452 in detecting ccRCC in patients with an indeterminate renal mass.

Panelists discuss how molecular imaging might help with complex renal mass decision-making, potentially identifying aggressive clear cell biology that would warrant radical rather than partial ...

Anne Schuckman, MD, on optimal sequencing strategies, the SWOG 1602 trial, and the emerging role of ctDNA. There has been an explosion in innovation in the non–muscle invasive bladder cancer (NMIBC) ...

Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete ...